{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:24:45Z","timestamp":1792225485592,"version":"4.4.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T00:00:00Z","timestamp":1736640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82230004"],"award-info":[{"award-number":["82230004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970113"],"award-info":[{"award-number":["81970113"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special Fund","doi-asserted-by":"publisher","award":["2022-1-4082"],"award-info":[{"award-number":["2022-1-4082"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2021YFC2500304"],"award-info":[{"award-number":["2021YFC2500304"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.canlet.2025.217460","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T11:10:58Z","timestamp":1736593858000},"page":"217460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Clinical features and prognostic nomogram for therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1016","volume":"612","author":[{"given":"Menglin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chencong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0245-6792","authenticated-orcid":false,"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.217460_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217460_bib2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217460_bib3","article-title":"Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217460_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112952","article-title":"Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy","volume":"191","author":"Lee","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2025.217460_bib5","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1002\/cncr.34453","article-title":"Epidemiologic outlook of therapy-related myeloid neoplasms and selection of high-risk patients: a Korean nationwide study","volume":"128","author":"Ha","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2025.217460_bib6","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1186\/s12885-020-07603-9","article-title":"Clinicopathological features, risk and survival in lung cancer survivors with therapy-related acute myeloid leukaemia","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2025.217460_bib7","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2013-07-512657","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"123","author":"Eichenauer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217460_bib8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","article-title":"Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era","volume":"5","author":"Morton","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2025.217460_bib9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41375-023-01864-6","article-title":"Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective","volume":"37","author":"Moreno","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2025.217460_bib10","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/bloodadvances.2021005335","article-title":"Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study","volume":"6","author":"Mart\u00ednez-Cuadr\u00f3n","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.canlet.2025.217460_bib11","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3324\/haematol.2022.281742","article-title":"Lessons learned from therapy-related acute myeloid leukemia","volume":"108","author":"Kayser","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2025.217460_bib12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3324\/haematol.2022.281233","article-title":"Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications","volume":"108","author":"Nilsson","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2025.217460_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-020-0316-3","article-title":"Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype","volume":"10","author":"Samra","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canlet.2025.217460_bib14","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world Health organization classification of haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2025.217460_bib15","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41409-020-01129-1","article-title":"ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation","volume":"56","author":"Jentzsch","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.canlet.2025.217460_bib16","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.3324\/haematol.2019.219352","article-title":"Genomics of therapy-related myeloid neoplasms","volume":"105","author":"Kuzmanovic","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2025.217460_bib17","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/s41375-023-01985-y","article-title":"Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification","volume":"37","author":"Hochman","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2025.217460_bib18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41409-023-01970-0","article-title":"Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study","volume":"58","author":"Baranwal","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.canlet.2025.217460_bib19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ajh.25395","volume":"94","author":"Lee","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2025.217460_bib20","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217460_bib21","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217460_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217018","article-title":"Single-cell transcriptomic analysis of the immune microenvironment in pediatric acute leukemia","volume":"596","author":"Yuan","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217460_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217158","article-title":"Sphingosine-1 phosphate receptor 1 (S1PR1) expression maintains stemness of acute myeloid leukemia stem cells","volume":"600","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217460_bib24","doi-asserted-by":"crossref","first-page":"16929","DOI":"10.1002\/cam4.6322","article-title":"Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France","volume":"12","author":"Belhabri","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2025.217460_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41408-023-00821-x","article-title":"TP53 mutation variant allele frequency of \u226510% is associated with poor prognosis in therapy-related myeloid neoplasms","volume":"13","author":"Shah","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canlet.2025.217460_bib26","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.canlet.2025.217460_bib27","article-title":"Nomogram predicts risk and prognostic factors for bone metastasis of pancreatic cancer: a population-based analysis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.canlet.2025.217460_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101523","article-title":"A prediction nomogram for neonatal acute respiratory distress syndrome in late-preterm infants and full-term infants: a retrospective study","volume":"50","author":"Liu","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.canlet.2025.217460_bib29","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/cid\/ciaa963","article-title":"Development and validation of a nomogram for assessing survival in patients with COVID-19 pneumonia","volume":"72","author":"Dong","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.canlet.2025.217460_bib30","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.urolonc.2017.07.018","article-title":"Toward an MRI-based nomogram for the prediction of transperineal prostate biopsy outcome: a physician and patient decision tool","volume":"35","author":"Lee","year":"2017","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.canlet.2025.217460_bib31","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2006.07.1290","article-title":"Are nomograms better than currently available stage groupings for bladder cancer?","volume":"24","author":"Sternberg","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217460_bib32","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1182\/blood-2009-10-249128","article-title":"Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia","volume":"115","author":"Litzow","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217460_bib81","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2005-05-2146","article-title":"Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched\/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation","volume":"109","author":"Lu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217460_bib82","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41409-024-02211-8","article-title":"A prognostic score system in adult T-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation","volume":"59","author":"Xiao","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.canlet.2025.217460_bib83","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/ajh.26312","article-title":"Clinical risk factors and prognostic model for idiopathic inflammatory demyelinating diseases after haploidentical hematopoietic stem cell transplantation in patients with hematological malignancies","volume":"96","author":"Deng","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2025.217460_bib84","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1038\/leu.2016.110","article-title":"Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant","volume":"30","author":"Wang","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2025.217460_bib85","doi-asserted-by":"crossref","first-page":"530","DOI":"10.21147\/j.issn.1000-9604.2024.05.06","article-title":"Quality-adjusted time without symptoms or toxicity analysis of haploidentical-related donor vs. identical sibling donor hematopoietic stem cell transplantation in acute myeloid leukemia","volume":"36","author":"Wang","year":"2024","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217460_bib33","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry","volume":"90","author":"Hulegardh","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2025.217460_bib34","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41467-021-21255-8","article-title":"The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms","volume":"12","author":"Schwartz","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.217460_bib35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bjh.16354","article-title":"How to address second and therapy-related acute myelogenous leukaemia","volume":"188","author":"Oliai","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2025.217460_bib36","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1038\/s41375-019-0520-y","article-title":"Risk of therapy-related myelodysplastic syndrome\/acute myeloid leukemia after childhood cancer: a population-based study","volume":"33","author":"Advani","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2025.217460_bib37","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2025.217460_bib38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1470-2045(16)30622-2","article-title":"Predicting therapy-related myeloid neoplasms-and preventing them?","volume":"18","author":"Steensma","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217460_bib39","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/leu.2013.368","article-title":"The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia","volume":"28","author":"Jacoby","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2025.217460_bib40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ajh.23605","article-title":"Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia","volume":"89","author":"Ornstein","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2025.217460_bib41","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3324\/haematol.2008.000927","article-title":"Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation","volume":"94","author":"Kr\u00f6ger","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2025.217460_bib42","doi-asserted-by":"crossref","first-page":"E80","DOI":"10.1002\/ajh.23966","article-title":"Characteristics and outcome of therapy-related myeloid neoplasms: report from the Italian network on secondary leukemias","volume":"90","author":"Fianchi","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2025.217460_bib43","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry","volume":"90","author":"Huleg\u00e5rdh","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2025.217460_bib44","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/bmt.2015.338","article-title":"Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation","volume":"51","author":"Finke","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.canlet.2025.217460_bib45","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/leu.2015.122","article-title":"Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment","volume":"30","author":"Sevcikova","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2025.217460_bib46","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1182\/blood.2022018108","article-title":"Overlapping features of therapy-related and de novo NPM1-mutated AML","volume":"141","author":"Othman","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217460_bib47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.biopha.2011.12.007","article-title":"Prognostic factors for therapy-related acute myeloid leukaemia (t-AML)--a single centre experience","volume":"66","author":"Suvajd\u017ei\u0107","year":"2012","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2025.217460_bib48","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1200\/JCO.2011.41.1215","article-title":"Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms","volume":"30","author":"Larson","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217460_bib49","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217460_bib50","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/modpathol.2014.153","article-title":"High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome","volume":"28","author":"Cleven","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.canlet.2025.217460_bib51","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.3324\/haematol.2014.118034","article-title":"High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia","volume":"100","author":"Karimi","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2025.217460_bib52","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41409-019-0673-3","article-title":"Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study","volume":"55","author":"Gatwood","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.canlet.2025.217460_bib53","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/s41409-022-01748-w","volume":"57","author":"Maffini","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.canlet.2025.217460_bib54","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/bmt.2008.226","article-title":"Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML","volume":"42","author":"Nevill","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.canlet.2025.217460_bib55","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/bloodadvances.2022009010","article-title":"Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia","volume":"7","author":"Lachowiez","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.canlet.2025.217460_bib56","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/ajh.26892","article-title":"Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia","volume":"98","author":"Lo","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2025.217460_bib57","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2025.217460_bib58","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41375-023-01846-8","article-title":"Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study","volume":"37","author":"Mrozek","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2025.217460_bib59","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41408-022-00764-9","article-title":"Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation","volume":"12","author":"Jentzsch","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canlet.2025.217460_bib60","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40164-024-00487-6","article-title":"Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system","volume":"13","author":"Zhang","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2025.217460_bib61","article-title":"Clinicopathologic and molecular analysis of normal karyotype therapy-related and de novo acute myeloid leukemia: a multi-institutional study by the bone marrow pathology group","volume":"7","author":"Cantu","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.canlet.2025.217460_bib62","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ajh.26589","article-title":"Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms","volume":"97","author":"Shah","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2025.217460_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217104","article-title":"Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia","volume":"598","author":"Yan","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217460_bib64","author":"Nagler","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2025.217460_bib65","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13287-024-03640-4","article-title":"Allogenic hematopoietic stem cell transplantation outcomes of patients aged >\/= 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study","volume":"15","author":"Gao","year":"2024","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.canlet.2025.217460_bib66","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","article-title":"Unified classification and risk-stratification in acute myeloid leukemia","volume":"13","author":"Tazi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.217460_bib67","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.217460_bib68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-015-0139-z","article-title":"TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases","volume":"8","author":"Ok","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2025.217460_bib69","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3324\/haematol.2011.051581","article-title":"Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia","volume":"97","author":"Fried","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2025.217460_bib70","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood.2022018236","article-title":"TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype","volume":"141","author":"Hiwase","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217460_bib71","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ajh.26118","article-title":"Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management","volume":"96","author":"Pardanani","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2025.217460_bib72","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/ajh.26962","article-title":"Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management","volume":"98","author":"Pardanani","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2025.217460_bib73","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217460_bib74","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/s41375-023-01909-w","article-title":"AML classification in the year 2023: how to avoid a Babylonian confusion of languages","volume":"37","author":"Huber","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2025.217460_bib75","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3324\/haematol.2011.040840","article-title":"TET2 mutations in secondary acute myeloid leukemias: a French retrospective study","volume":"96","author":"Kosmider","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2025.217460_bib76","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/bmt.2017.52","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma","volume":"52","author":"Yamasaki","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.canlet.2025.217460_bib77","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00259-020-05127-9","article-title":"Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival","volume":"48","author":"Chantadisai","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.canlet.2025.217460_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216937","article-title":"Activation of PPAR\u03b4 in bone marrow endothelial progenitor cells improves their hematopoiesis-supporting ability after myelosuppressive injury","volume":"592","author":"Liang","year":"2024","journal-title":"Cancer Lett."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525000242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525000242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T22:57:35Z","timestamp":1760741855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525000242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":83,"alternative-id":["S0304383525000242"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217460","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features and prognostic nomogram for therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217460"}}